[Homozygous beta-thalassemia and hepatic enzymes].

R. Miniero,P. Tovo,L. Sacchetti,A. Iavarone

1977-08-01

Minerva Pediatrica

Abstract:

What problem does this paper attempt to address?

Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major

Maria Musumeci,Vincenzo Caruso,Emilia Medulla,Venerando Torrisi,Roberta Migale,Silvia Angeletti,Salvatore Musumeci

DOI: https://doi.org/10.1155/2014/965971

Abstract:Background: YKL-40 association with human disease has been the object of many years of investigation. β-thalassemia patients are affected by hepatic siderosis, which determines a fibrotic process and tissue remodelling. Chitotriosidase has been found to be increased in thalassemic patients returning to normal in patients submitted to bone marrow transplantation. YKL-40 is associated with macrophage activation in liver and in other tissues. The aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis. Methods: Expression of YKL-40 and chitotriosidase as a marker of inflammation in 69 thalassemic patients were evaluated. We sought to investigate whether these two chitinases could be considered as a significant biomarker to evaluate therapy effectiveness. Results: Surprisingly we found normal value of YKL-40. We, also, analysed chitotriosidase activity in the same patients that was slightly increased as a consequence of macrophage activation. Conclusions: These data would suggest a good treatment for these patients.
S4368 Atypical Presentation of Beta-Thalassemia Trait with Heterozygous H63D Mutation: Hemolysis, Iron Overload, and Liver Cirrhosis

Meetkumar V. Pipaliya,Ritesh Prajapati,Mipasha Patel,Litinkumar V. Sardhara

DOI: https://doi.org/10.14309/01.ajg.0001046840.19107.a9

2024-10-26

The American Journal of Gastroenterology

Abstract:Neither the beta-thalassemia trait (BTT) nor the heterozygous state for the H63D mutation of the hereditary hemochromatosis gene (HFE gene) alone leads to iron overload. However, when inherited together, iron overload may occur. Here, we describe a patient with this rare co-occurrence who developed secondary hemochromatosis and liver cirrhosis.

gastroenterology & hepatology
Effects of chemical and enzymatic modifications on starch-oleic acid complex formation.

E. Arijaje,Ya‐Jane Wang

DOI: https://doi.org/10.1021/acs.jafc.5b00125

IF: 6.1

2015-04-21

Journal of Agricultural and Food Chemistry

Abstract:The solubility of starch-inclusion complexes affects the digestibility and bioavailability of the included molecules. Acetylation with two degrees of substitution, 0.041 (low) and 0.091 (high), combined without or with a β-amylase treatment was employed to improve the yield and solubility of the inclusion complex between debranched potato starch and oleic acid. Both soluble and insoluble complexes were recovered and analyzed for their degree of acetylation, complexation yields, molecular size distributions, X-ray diffraction patterns, and thermal properties. Acetylation significantly increased the amount of recovered soluble complexes as well as the complexed oleic acid in both soluble and insoluble complexes. High-acetylated debranched-only starch complexed the highest amount of oleic acid (38.0 mg/g) in the soluble complexes; low-acetylated starch with or without the β-amylase treatment resulted in the highest complexed oleic acid in the insoluble complexes (37.6-42.9 mg/g). All acetylated starches displayed the V-type X-ray pattern, and the melting temperature generally decreased with acetylation. The results indicate that starch acetylation with or without the β-amylase treatment can improve the formation and solubility of the starch-oleic acid complex.
Characterization and Clinical Assessment of a Peculiar Case of Hemolytic Anemia

Fulvio Castelgrande,Gemma Viola,Cinzia Calabrese,Mariannina Iozzo,Renato Massoud,Massimo Pieri,Marilena Minieri,Gaspare Adorno,Sergio Bernardini,Alessandro Terrinoni

DOI: https://doi.org/10.14740/jh1204

Abstract:Thalassemic diseases are characterized by a reduced (β+) or absent (β0) synthesis of the globin chains of hemoglobin (Hb) due to genetic mutations. β-thalassemia was more frequent in the Mediterranean area, but now it is diffused worldwide. Three possible genetic forms can be distinguished: β0/β0, the most severe (Cooley's disease); β0/β+ of intermediate severity; β+/β+ associated with β-thalassemia intermedia or minor. Recently, a clinical non-genetic classification has been proposed: transfusion-dependent thalassemia (TDT), requiring regular lifetime blood transfusions, and non-transfusion-dependent thalassemia (NTDT), requiring occasional transfusions to manage acute cases. In this report, we studied a patient whose blood count indicated a severe anemia but also showed thrombocytosis, leukocytosis, and an elevated number of nucleated red blood cells (NRBC). These altered blood parameters suggested initially a possible diagnosis of hemoglobinopathy or myeloproliferative syndrome. The molecular and genetic analyses demonstrated the presence of HbF (5.3%) and HbA2 (7.7%) and the presence of the homozygote mutation (IVS1.6T>C) in the β-globin gene. According to these data, a diagnosis of β-thalassemia intermedia form has been proposed. Nevertheless, the clinical condition, the presence of thrombocytosis, leukocytosis, an elevated number of NRBC, and the frequent blood transfusions lead to reclassification of the patient as TDT subject. Consequently, this result suggests that a unique genotype-phenotype correlation is not possible in the presence of β+mutations since other concomitant pathologies can exacerbate the disease.
Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

Antonella Meloni,Laura Pistoia,Paolo Ricchi,Sergio Bagnato,Filomena Longo,Giuseppe Messina,Sabrina Bagnato,Vincenza Rossi,Stefania Renne,Riccardo Righi,Priscilla Fina,Vincenzo Positano,Filippo Cademartiri,Cademartiri, Filippo

DOI: https://doi.org/10.1007/s00277-024-05741-9

2024-04-07

Annals of Hematology

Abstract:We evaluated the impact of the genotype on clinical and hematochemical features, hepatic and cardiac iron levels, and endocrine, hepatic, and cardiovascular complications in non-transfusion-dependent (NTD) β-thalassemia intermedia (TI) patients. Sixty patients (39.09 ± 11.11 years, 29 females) consecutively enrolled in the Myocardial Iron Overload in Thalassemia project underwent Magnetic Resonance Imaging to quantify iron overload, biventricular function parameters, and atrial areas and to detect replacement myocardial fibrosis. Three groups of patients were identified: homozygous β+ ( N = 18), heterozygous β0β+ ( N = 22), and homozygous β0 ( N = 20). The groups were homogeneous for sex, age, splenectomy, hematochemical parameters, chelation therapy, and iron levels. The homozygous β° genotype was associated with significantly higher biventricular end-diastolic and end-systolic volume indexes and bi-atrial area indexes. No difference was detected in biventricular ejection fractions or myocardial fibrosis. Extramedullary hematopoiesis and leg ulcers were significantly more frequent in the homozygous β° group compared to the homozygous β+ group. No association was detected between genotype and liver cirrhosis, hypogonadism, hypothyroidism, osteoporosis, heart failure, arrhythmias, and pulmonary hypertension. Heart remodelling related to a high cardiac output state cardiomyopathy, extramedullary hematopoiesis, and leg ulcers were more pronounced in patients with the homozygous β° genotype compared to the other genotypes analyzed. The knowledge of the genotype can assist in the clinical management of NTD β-TI patients.

hematology
Analysis of Genotypes and Clinical Manifestations of 54 Patients with β-thalassemia

R. Zhao

Abstract:Objective To explore the relationship between gene mutations of β thalassemia and clinical manifestations.Methods Polymerase chain reaction and reverse dot blot were used to study molecular characterization of β globin gene mutations in 54 patients with β thalassemia.Resutes Eight different mutations were identified. There were 13 genotypes.Conclusion The homozygote β 0 and β 0/β 0 had severe clinical course, severe anemia and earlier onset. The dual heterozygenes β 0/β + had moderate or severe clinical course, later onset and light anemia.

Medicine
Αlpha-thalassemia: A practical overview

Khaled M. Musallam,M. Domenica Cappellini,Thomas D. Coates,Kevin H.M. Kuo,Hanny Al-Samkari,Sujit Sheth,Vip Viprakasit,Ali T. Taher

DOI: https://doi.org/10.1016/j.blre.2023.101165

IF: 10.626

2024-01-05

Blood Reviews

Abstract:α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and thus varying degrees of ineffective erythropoiesis, decreased red blood cell (RBC) survival, chronic hemolytic anemia, and subsequent comorbidities. Clinical presentation varies depending on the genotype, ranging from a silent or mild carrier state to severe, transfusion-dependent or lethal disease. Management of patients with α-thalassemia is primarily supportive, addressing either symptoms (eg, RBC transfusions for anemia), complications of the disease, or its transfusion-dependence (eg, chelation therapy for iron overload). Several novel therapies are also in development, including curative gene manipulation techniques and disease modifying agents that target ineffective erythropoiesis and chronic hemolytic anemia. This review of α-thalassemia and its various manifestations provides practical information for clinicians who practice beyond those regions where it is found with high frequency.

hematology
Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

Vincenzo Russo,Enrico Melillo,Andrea A Papa,Anna Rago,Celeste Chamberland,Gerardo Nigro

DOI: https://doi.org/10.1155/2019/9319832

2019-11-30

Abstract:Beta-thalassemias are a group of inherited, autosomal recessive diseases, characterized by reduced or absent synthesis of beta-globin chains of the hemoglobin tetramer, resulting in variable phenotypes, ranging from clinically asymptomatic individuals to severe anemia. Three main forms have been described: heterozygotes, homozygotes β+, and homozygotes β°. Beta-thalassemia major (β-TM), the most serious form, is characterized by an absent synthesis of globin chains that are essential for hemoglobin formation, causing chronic hemolytic anemia. Cardiac complications represent a leading cause of mortality in β-TM patients, although an important and progressive increase of life expectancy has been demonstrated after the introduction of chelating therapies. Iron overload is the primary factor of cardiac damage resulting in thalassemic cardiomyopathy, in which diastolic dysfunction usually happens before systolic impairment and overt heart failure (HF). Although iron-induced cardiomyopathy is slowly progressive and it usually takes several decades for clinical and laboratory features of cardiac dysfunction to manifest, arrhythmias or sudden death may be present without signs of cardiac disease and only if myocardial siderosis is present. Careful analysis of electrocardiograms and other diagnostic tools may help in early identification of high-risk β-TM patients for arrhythmias and sudden cardiac death.
Multi-Omics Analysis in β-Thalassemia Using an HBB Gene-Knockout Human Erythroid Progenitor Cell Model

Guoqiang Zhou,Haokun Zhang,Anning Lin,Zhen Wu,Ting Li,Xumin Zhang,Hongyan Chen,Daru Lu

DOI: https://doi.org/10.3390/ijms23052807

IF: 5.6

2022-03-04

International Journal of Molecular Sciences

Abstract:β-thalassemia is a hematologic disease that may be associated with significant morbidity and mortality. Increased expression of HBG1/2 can ameliorate the severity of β-thalassemia. Compared to the unaffected population, some β-thalassemia patients display elevated HBG1/2 expression levels in their red blood cells. However, the magnitude of up-regulation does not reach the threshold of self-healing, and thus, the molecular mechanism underlying HBG1/2 expression in the context of HBB-deficiency requires further elucidation. Here, we performed a multi-omics study examining chromatin accessibility, transcriptome, proteome, and phosphorylation patterns in the HBB homozygous knockout of the HUDEP2 cell line (HBB-KO). We found that up-regulation of HBG1/2 in HBB-KO cells was not induced by the H3K4me3-mediated genetic compensation response. Deletion of HBB in human erythroid progenitor cells resulted in increased ROS levels and production of oxidative stress, which led to an increased rate of apoptosis. Furthermore, in response to oxidative stress, slower cell cycle progression and proliferation were observed. In addition, stress erythropoiesis was initiated leading to increased intracellular HBG1/2 expression. This molecular model was also validated in the single-cell transcriptome of hematopoietic stem cells from β-hemoglobinopathy patients. These findings further the understanding of HBG1/2 gene regulatory networks and provide novel clinical insights into β-thalassemia phenotypic diversity.

biochemistry & molecular biology,chemistry, multidisciplinary
Study of iron complexes in visceral organs and brain from a ${}^57$Fe enriched $β$-thalassaemia mouse model via Mössbauer Spectroscopy

G. Charitou,Ch. Tsertos,Y. Parpottas,M. Kleanthous,C. Lederer,M. Phylactides

DOI: https://doi.org/10.48550/arXiv.2006.01511

2020-06-02

Biological Physics

Abstract:The hearts, kidneys, livers, spleens and brains of ${}^57$Fe enriched wild-type and heterozygous $\beta$-thalassaemic mice at 1, 3, 6 and 9 months of age were studied by means of M\"ossbauer Spectroscopy at 80K. Ferritin-like iron depositions in the heart and the brain of the thalassaemic mice were found to be slightly increased while significant amounts of Ferritin-like iron were found in the kidneys, liver and spleen. The ferritin-like iron doublet, found in the organs, could be further separated into two sub-doublets representing the inner and surface structures of ferritin mineral core. Surface iron sites were found to be predominant in the hearts and brains of all mice and in the kidneys of the wild-type animals. Ferritin rich in inner iron sites was predominant in the kidneys of the thalassaemic mice, as well as in the livers and in the spleens. The inner-to-surface iron sites ratio was elevated in all thalassaemic samples indicating that besides ferritin amount, the disease can also affect ferritin mineral core structure.
Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait

Kuo, Kevin H. M.

DOI: https://doi.org/10.1007/s00277-024-06007-0

2024-09-25

Annals of Hematology

Abstract:There is a group of beta (β)-thalassemia trait 'carriers' (with heterozygous mutations) who should be asymptomatic with minor abnormalities in their hematological parameters, but experience more severe disease manifestations than predicted based solely on their β-globin genotype. This review focuses on literature describing trans -acting genetic modifiers outside of the α- and β-globin gene clusters that could cause this phenomenon. These genetic modifiers are categorized into: mutations affecting the quantity of alpha-globin products, non-globin mutations affecting erythropoiesis, membranopathies, enzymopathies and erythrocyte-independent modifiers of complications relating to β-thalassemia. Although some genetic determinants seem to correlate more directly with β-thalassemia trait severity, such as mutations in SUPT5H , PIEZO1 and hereditary elliptocytosis, the difficulties of linking the contribution of other modulating factors are elucidated in this review. Targeted next generation sequencing of hemolytic anemias can be helpful but also raises another quandary in interpreting variants of uncertain significance. The accrual of knowledge, along with the increased availability of genetic testing for genetic modifiers has considerable potential for clinical applications such as genetic counselling, decision-making for clinical interventions and prognostication, and perhaps generating new therapeutic targets.

hematology
Endocrinopathies in beta thalassemia: a narrative review

Theodora-Maria Venou,Fani Barmpageorgopoulou,Melpomeni Peppa,Efthimia Vlachaki

DOI: https://doi.org/10.1007/s42000-023-00515-w

Abstract:Beta thalassemia is the most common genetic blood disorder, characterized by reduced production or complete absence of beta-globin chains. The combination of systematic red blood cell transfusion and iron chelation therapy is the most readily available supportive treatment and one that has considerably prolonged the survival of thalassemia patients. Despite this, the development of endocrine abnormalities correlated with beta thalassemia still exists and is mostly associated with iron overload, chronic anemia, and hypoxia. A multifactorial approach has been employed to investigate other factors involved in the pathogenesis of endocrinopathies, including genotype, liver disease, HCV, splenectomy, socioeconomic factors, chelation therapy, and deficiency of elements. The development of specific biomarkers for predicting endocrinopathy risk has been the subject of extensive discussion. The objective of the present narrative review is to present recent data on endocrinopathies in beta thalassemia patients, including the prevalence, the proposed pathogenetic mechanisms, the risk factors, the diagnostic methods applied, and finally the recommended treatment options.
COMMUNITY OWNERSHIP AND MANAGEMENT OF WATER AND SANITATION FACILITIES: ISSUES AND PROSPECTS IN THE NADOWLI DISTRICT OF THE UPPER WEST REGION OF GHANA

I. Braimah,N. Fielmua,K. Nkrumah

Abstract:Over the last decade, community ownership and management (COM) has become the leading concept in rural water and sanitation provisions in Ghana. The purpose of this study was to assess the main issues and prospects of COM as a strategy for improving sustainable access to rural water and sanitation in the Nadowli District of the Upper West Region of Ghana. The main issues identified included community participation, access to spare parts, effectiveness of water and sanitation related institutions, economic situation of the people, and availability of alternative sources of water. The study revealed that the prospects of COM ensured that sustainability was good, but it depended on how the District Assembly (DA) addressed the major challenges of poverty and transparency of the relevant institutions.
Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia

Jyoti Shaw,Abhilipsa Patra,Anjumana Khatun,Rudra Ray,Amit Ghosh,Sonali Mahapatra,Ashutosh Panigrahi,Maitreyee Bhattacharyya

DOI: https://doi.org/10.1002/jha2.923

2024-05-27

eJHaem

Abstract:The phenotype of β-thalassemia varies widely. The primary determinant is the type of beta-globin gene mutation; however, there are secondary and tertiary modifiers also as associated alpha mutations, polymorphisms, as well as coinheritance of mutations affecting other related systems. Co-inheritance of alpha thalassemia mutations is known to ameliorate the severity of HbE-β thalassemia. However, the role of alpha globin gene alterations (deletions and triplication) is not well illustrated in homozygous β-thalassemia. Here we evaluated the role of alpha globin gene alterations in 122 β-thalassemia patients having IVS1-5 (G > C) homozygous mutation. β-thalassemia mutations were detected by ARMS PCR and alpha mutations by GAP-PCR. Gene expression by qRT-PCR. Out of 122 cases, 15 patients had alpha 3.7 triplications (ααα3.7anti), 24 had alpha 3.7 kb deletion (-α3.7) mutation and three patients had 4.2 kb deletion (-α4.2). Patients were divided into two groups, requiring less than 8 units (NTDT) and more than 8 units (TDT) of blood transfusion per year (≥8U BT/year). The percentage of alpha deletion was significantly (p = 0.0042) high in NTDT (42.1%) as compared with TDT (13.2%). Conversely, the proportion of alpha triplication is high in the TDT as compared with NTDT. Even mean serum ferritin level was found to be significantly high in patients having alpha triplication as compared with those having alpha deletions (p = 0.0184) and normal alpha gene (p = 0.0003). α/β globin ratio was highest in TDT patients with alpha triplication and lowest in NTDT patients with alpha-del. The results show that concurrent inheritance of alpha gene alterations influences the phenotypic severity of homozygous β-thalassemia.
Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia

Na Li,Peng An,Jifeng Wang,Tingting Zhang,Xiaoqing Qing,Bowen Wu,Lang Sun,Xiang Ding,Lili Niu,Zhensheng Xie,Mengmeng Zhang,Xiaojing Guo,Xiulan Chen,Tanxi Cai,Jianming Luo,Fudi Wang,Fuquan Yang

DOI: https://doi.org/10.1016/j.isci.2022.104091

IF: 5.8

2022-04-01

iScience

Abstract:The phenotype of β-thalassemia underlies multigene interactions, making clinical stratification complicated. An increasing number of genetic modifiers affecting the disease severity have been identified, but are still unable to meet the demand of precision diagnosis. Here, we systematically conducted a comparative plasma proteomic profiling on patients with β-thalassemia and healthy controls. Among 246 dysregulated proteins, 13 core protein signatures with excellent biomarker potential are proposed. The combination of proteome and patients' clinical data revealed patients with codons 41/42 -TTCT mutations have an elevated risk of higher iron burden, dysplasia, and osteoporosis than patients with other genotypes. Notably, 85 proteins correlating to fetal hemoglobin (Hb F) were identified, among which the abundance of 27 proteins may affect the transfusion burden in patients with β-thalassemia. The current study thus provides protein signatures as potential diagnostic biomarkers or therapeutic clues for β-thalassemia.

multidisciplinary sciences
Fetal Hemoglobin Regulation in Beta-Thalassemia

Henry Y Lu,Stuart H Orkin,Vijay G Sankaran

DOI: https://doi.org/10.1016/j.hoc.2022.12.002

Abstract:β-thalassemia is caused by mutations that reduce β-globin production, causing globin chain imbalance, ineffective erythropoiesis, and consequent anemia. Increased fetal hemoglobin (HbF) levels can ameliorate the severity of β-thalassemia by compensating for the globin chain imbalance. Careful clinical observations paired with population studies and advances in human genetics have enabled the discovery of major regulators of HbF switching (i.e. BCL11A, ZBTB7A) and led to pharmacological and genetic therapies for treating β-thalassemia patients. Recent functional screens using genome editing and other emerging tools have identified many new HbF regulators, which may improve therapeutic HbF induction in the future.
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Irene Motta,Rayan Bou-Fakhredin,Ali T. Taher,Maria Domenica Cappellini

DOI: https://doi.org/10.1007/s40265-020-01341-9

2020-06-15

Drugs

Abstract:Hemoglobinopathies are among the most common monogenic diseases worldwide. Approximately 1–5% of the global population are carriers for a genetic thalassemia mutation. The thalassemias are characterized by autosomal recessive inherited defects in the production of hemoglobin. They are highly prevalent in the Mediterranean, Middle East, Indian subcontinent, and East and Southeast Asia. Due to recent migrations, however, the thalassemias are now becoming more common in Europe and North America, making this disease a global health concern. Currently available conventional therapies in thalassemia have many challenges and limitations. A better understanding of the pathophysiology of β-thalassemia in addition to key developments in optimizing transfusion programs and iron-chelation therapy has led to an increase in the life span of thalassemia patients and paved the way for new therapeutic strategies. These can be classified into three categories based on their efforts to address different features of the underlying pathophysiology of β-thalassemia: correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload. In this review, we provide an overview of the novel therapeutic approaches that are currently in development for β-thalassemia.

pharmacology & pharmacy,toxicology
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia

G. Lugthart,E. J. T. Verweij,C. L. Harteveld,R. N. G. B. Tan,M. F. C. M. Knapen,F. Slaghekke,M. C. Haak,A. B. Mohseny,F. J. Smiers

DOI: https://doi.org/10.1002/ajh.27344

IF: 13.265

2024-04-26

American Journal of Hematology

Abstract:Intra‐uterine reduction of Hb Bart's only reached with exchange transfusions.

hematology
Preliminary screening of biomarkers and drug candidates in a mouse model of β-thalassemia based on quasi-targeted metabolomics

Xianfeng Guo,Xuchao Zhang,Min Li,Yuanliang Peng,Zi Wang,Jing Liu

DOI: https://doi.org/10.3389/fphys.2024.1452558

2024-08-23

Abstract:Background: β-thalassemia (β-TH) is a hereditary hemolytic anemia that results in deficient hemoglobin (Hb) synthesis. It is characterized by ineffective erythropoiesis, anemia, splenomegaly, and systemic iron overload. Exploration new potential biomarkers and drug candidates is important to facilitate the prevention and treatment of β-TH. Methods: We applied quasi-targeted metabolomics between wild type (Wt) and heterozygous β-TH mice (Th3/+), a model of non-transfusion-dependent β-TH intermedia, in plasma and peripheral blood (PB) cells. Futher data was deeply mined by Kyoto Encyclopedia of Genomes (KEGG) and machine algorithms methods. Results: Using KEGG enrichment analysis, we found that taurine and hypotaurine metabolism disorders in plasma and alanine, aspartate and glutamate metabolism disorders in PB cells. After systematically anatomize the metabolites by machine algorithms, we confirmed that alpha-muricholic acidUP and N-acetyl-DL-phenylalanineUP in plasma and Dl-3-hydroxynorvalineUP, O-acetyl-L-serineUP, H-abu-OHUP, S-(Methyl) glutathioneUP, sepiapterinDOWN, and imidazoleacetic acidDOWN in PB cells play key roles in predicting the occurrence of β-TH. Furthermore, Sepiapterin, Imidazoleacetic acid, Methyl alpha-D-glucopyranoside and alpha-ketoglutaric acid have a good binding capacity to hemoglobin E through molecular docking and are considered to be potential drug candidates for β-TH. Conclusion: Those results may help in identify useful molecular targets in the diagnosis and treatment of β-TH and lays a strong foundation for further research.
[Physiology and pathophysiology of bile acids in infancy and childhood].

H. Senger,W. Braun,K. Beyreiss,G. Boehm

Abstract:

[Homozygous beta-thalassemia and hepatic enzymes].

Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major

S4368 Atypical Presentation of Beta-Thalassemia Trait with Heterozygous H63D Mutation: Hemolysis, Iron Overload, and Liver Cirrhosis

Effects of chemical and enzymatic modifications on starch-oleic acid complex formation.

Characterization and Clinical Assessment of a Peculiar Case of Hemolytic Anemia

Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

Analysis of Genotypes and Clinical Manifestations of 54 Patients with β-thalassemia

Αlpha-thalassemia: A practical overview

Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

Multi-Omics Analysis in β-Thalassemia Using an HBB Gene-Knockout Human Erythroid Progenitor Cell Model

Study of iron complexes in visceral organs and brain from a ${}^57$Fe enriched $β$-thalassaemia mouse model via Mössbauer Spectroscopy

Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait

Endocrinopathies in beta thalassemia: a narrative review

COMMUNITY OWNERSHIP AND MANAGEMENT OF WATER AND SANITATION FACILITIES: ISSUES AND PROSPECTS IN THE NADOWLI DISTRICT OF THE UPPER WEST REGION OF GHANA

Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia

Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia

Fetal Hemoglobin Regulation in Beta-Thalassemia

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia

Preliminary screening of biomarkers and drug candidates in a mouse model of β-thalassemia based on quasi-targeted metabolomics

[Physiology and pathophysiology of bile acids in infancy and childhood].